On March 25, 2026, Incyte Corporation (NASDAQ: INCY) disclosed significant changes within its executive leadership team through a Form 8-K filing. The company announced that Pablo J. Cagnoni, M.D., has been appointed as the President of Incyte and Global Head of Research and Development. This change reflects the company's strategic focus on enhancing its research capabilities and operational execution. Dr. Cagnoni will continue to oversee the Research and Development department, which has made notable advancements in various therapeutic programs, including mutCALR antibody and povorcitinib.

Additionally, Steven H. Stein, M.D., has been appointed as the Executive Vice President, Chief Medical Officer, and Head of Late-stage Development. Dr. Stein will manage Incyte's growing late-stage development programs across Hematology, Oncology, and Immunology, reinforcing the company's commitment to scientific leadership in the healthcare community.

Mohamed Issa, Pharm.D., has also been appointed as the Executive Vice President and Head of U.S. Commercial, where he will oversee the integration of the U.S. Oncology and Immunology business units into a single commercial organization. This restructuring aims to enhance operational effectiveness and standardize best practices for new product launches.

The changes come as part of Incyte's ongoing efforts to align its leadership with its long-term growth strategy. The company emphasized that there were no changes to the compensation arrangements for the impacted executives as a result of these title changes. The leadership transition is expected to drive effective execution and position Incyte for future success in the biopharmaceutical industry.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.